| Objective:To observe the effect and drug side effects of ginsenoside Rg3treated stage III-IV of postoperatively endometriosis, and compare with gestrinone. Further explore the relationship between ginsenoside Rg3and angiogenesis, and explore mechanism of ginsenoside Rg3treatment of endometrial endometriosis.Methods:Select62women age between20-45years old,who with stage III-IV(stage standards by r-AFS) ovarian endometrial cyst and underwent laparotomy or laparoscopic operation in Wowen and Children’s hospital of Shanxi Province, and all confirm by pathology postoperative. All patients with menstrual cycle rules, have no endocrine disorder or immunological and metabolic diseases; routine preoperative laboratory tests of liver and kidney functions were normal, check tumor biomarkers to exclusive malignancy, three months before surgery did not receive hormone therapy. After operation they were randonly divided into2groups:study group with32patients who were received ginsenoside Rg3and all signing of the medication informed consent, positive control group with30patients who were prescribed gestrinone. The two groups have no statistical significant in age, course of the disease and the AFS score (P>0.05) Research group and the control group were positive in continuous use of medicine after surgery for3months:the study group were treated with ginsenoside Rg3in20mg/once/day; positive control group were treated with gestrinone,2.5mg/day,2times/week.We followed up each group for postoperative1month and3months and compared of pain (VAS score) before and after treatment, gynecological examination, pelvic ultrasound, liver function and CA125changes, adverse drug reaction of the two groups, etc. Specimen collection:collect the4ml blood of median cubital vein at8-9am of preoperative and1month and3month review, centrifugal them, save the serum in-80℃refrigerator, the ELISA method to measure serum VEGF and MMP-9value.Results:1. After treatment of one month and three month the pain score (VAS score) eased significantly (P<0.05) than before, and gradually decreased with the increase of treatment time (P<0.05), the comparation of the two groups to was not statistically significant (P>0.05);2. Significantly alleviate pelvic masses and tenderness nodules than before treatment After treatment, and the difference was statistically significant (P<0.05), between the two groups compared was no significant difference (P>0.05);3. The CA125of serum was decreased significantly (P<0.05) after treatment than before the surgery in the two groups, and decreases with the increase of treatment time (P<0.05), there were no significant difference between the two groups(P>0.05);4. There was no obviously change of the ALT、AST and GGT of serum in study groups after treatment than before (P>0.05),1month and3month after treatment of in positive control groups, the ALT and AST of serum had rised (P<0.05), the GGT of had rised after3month treatment (P<0.05), there were statistical differences between the two groups (P<0.05);5. Ginsenoside Rg3group had lower adverse drug reaction rate than gestrinone group (P<0.05)6. During the time of observing, three month after surgery, the VEGF of serum of ginsenoside Rg3group was lower than before surgery (P<0.05), but had no significant change in the the gestrinone group(P>0.05), and between the two groups therewas statistically significant difference (P<0.05).7. The MMP-9of serum was gradually declining as the application time went by (P<0.05), there were no obvious difference between the two groups(P>0.05);Conclusion:1.Ginsenoside Rg3has a better therapeutic effect in patients with endometriosis, fairly with the positive control of gestrinone;2. Ginsenoside Rg3in the treatment of endometriosis has no abnormal liver function, but some patients with gestrinone treatment suffered liver damage, it indicates that oral administration of ginsenoside Rg3is relatively safe;3.The patient’s menstrual cycle is normal in the ginsenoside Rg3treatment of endometriosis, but in gestrinone treatment the patients with amenorrhea or abnormal uterine bleeding, indicating that the effect of ginsenoside Rg3on the menstrual cycle without interference, while gestrinone is influential;4. The VEGF of serum of ginsenoside Rg3group is significantly lower than gestrinone group, this indicates that ginsenoside Rg3may be inhibiting angiogenesis of endometriosis patients to play a role; the value of MMP-9of serum of the two groups were significantly lower after treatment. may be that ginsenoside Rg3and gestrinone inhibits the invation of endometriosis from different ways.5. Ginsenoside Rg3have a certain therapeutic effect on endometriosis, may be an effective and safe adjuvant drug conservative surgery of endometriosis in clinical. |
PDF Full Text Request